260 reports of this reaction
1.7% of all TRIAZOLAM reports
#15 most reported adverse reaction
LOSS OF CONSCIOUSNESS is the #15 most commonly reported adverse reaction for TRIAZOLAM, manufactured by Pharmacia & Upjohn Company LLC. There are 260 FDA adverse event reports linking TRIAZOLAM to LOSS OF CONSCIOUSNESS. This represents approximately 1.7% of all 15,429 adverse event reports for this drug.
TRIAZOLAM has an overall safety score of 85 out of 100. Patients taking TRIAZOLAM who experience loss of consciousness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
LOSS OF CONSCIOUSNESS is a less commonly reported adverse event for TRIAZOLAM, but still significant enough to appear in the safety profile.
In addition to loss of consciousness, the following adverse reactions have been reported for TRIAZOLAM:
The following drugs have also been linked to loss of consciousness in FDA adverse event reports:
LOSS OF CONSCIOUSNESS has been reported as an adverse event in 260 FDA reports for TRIAZOLAM. This does not prove causation, but indicates an association observed in post-market surveillance data.
LOSS OF CONSCIOUSNESS accounts for approximately 1.7% of all adverse event reports for TRIAZOLAM, making it a notable side effect.
If you experience loss of consciousness while taking TRIAZOLAM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.